Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06750471
PHASE4

Dupixent Study for Alternate Administration

Sponsor: Madigan Army Medical Center

View on ClinicalTrials.gov

Summary

Investigators will investigate an alternate Dupilumab administration schedule in patients with recurrent chronic rhinosinusitis with nasal polyposis, who have a history of full endoscopic sinus surgery and are on appropriate topical medical therapies. Specifically, investigators will investigate if the alternate schedule of drug administration is non-inferior in both subjective and objective outcomes.

Official title: Efficacy of Alternate Dupilumab Schedule in Recurrent Chronic Rhinosinusitis With Nasal Polyposis Patients

Key Details

Gender

All

Age Range

18 Years - 100 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2021-10-14

Completion Date

2025-12

Last Updated

2025-01-17

Healthy Volunteers

Yes

Interventions

BIOLOGICAL

Dupilumab

Dupilumab is an anti-IL 4-13 biologic therapy that has been recently approved for use in recurrent chronic rhinosinusitis with nasal polyposis.

Locations (1)

Madigan Army Medical Center

Tacoma, Washington, United States